{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:25:47Z","timestamp":1782854747992,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1124\/dmd.115.068213","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T02:45:06Z","timestamp":1450233906000},"page":"378-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition"],"prefix":"10.1016","volume":"44","author":[{"given":"Attarat","family":"Pattanawongsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod C","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O","family":"Miners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.115.068213_bib1","series-title":"Australian Medicines Handbook","first-page":"767","article-title":"Psychotropic drugs","year":"2015"},{"key":"10.1124\/dmd.115.068213_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-198604000-00001","article-title":"Amitriptyline pharmacokinetics and clinical response: I. Free and total plasma amitriptyline and nortriptyline","volume":"1","author":"Baumann","year":"1986","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1124\/dmd.115.068213_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2125.2002.01669.x","article-title":"In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine","volume":"54","author":"Boase","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068213_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.fpc.0000197465.14340.d4","article-title":"Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir","volume":"16","author":"Boyd","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.115.068213_bib5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/jps.1027","article-title":"Ring flexibility within tricyclic antidepressant drugs","volume":"90","author":"Casarotto","year":"2001","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.115.068213_bib6","doi-asserted-by":"crossref","first-page":"9024","DOI":"10.1158\/0008-5472.CAN-07-2245","article-title":"Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.115.068213_bib7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/dmd.107.019406","article-title":"Glucuronidation of tobacco-specific nitrosamines by UGT2B10","volume":"36","author":"Chen","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/FPC.0b013e328348c76b","article-title":"Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants","volume":"21","author":"Erickson-Ridout","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.115.068213_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/clpt.1983.206","article-title":"Multiple-dose doxepin kinetics in depressed patients","volume":"34","author":"Faulkner","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068213_bib10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/jpet.114.220194","article-title":"A UGT2B10 splicing polymorphism common in African populations may greatly increase drug exposure","volume":"352","author":"Fowler","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.115.068213_bib11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1124\/dmd.30.9.991","article-title":"N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases","volume":"30","author":"Ghosheh","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib12","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jpba.2011.03.034","article-title":"Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition","volume":"55","author":"Guo","year":"2011","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.115.068213_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/clpt.1983.103","article-title":"Mianserin kinetics in depressed patients","volume":"33","author":"Hrdina","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.068213_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1008100132405","article-title":"Morphological similarity: a 3D molecular similarity method correlated with protein-ligand recognition","volume":"14","author":"Jain","year":"2000","journal-title":"J Comput Aided Mol Des"},{"key":"10.1124\/dmd.115.068213_bib15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1021\/jm030520f","article-title":"Ligand-based structural hypotheses for virtual screening","volume":"47","author":"Jain","year":"2004","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.115.068213_bib16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1006\/bbrc.1993.1847","article-title":"cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily","volume":"194","author":"Jin","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.115.068213_bib17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1124\/mol.107.037093","article-title":"Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10","volume":"72","author":"Kaivosaari","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.115.068213_bib18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1124\/dmd.108.021709","article-title":"Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes","volume":"36","author":"Kaivosaari","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3109\/00498254.2011.563327","article-title":"N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases","volume":"41","author":"Kaivosaari","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.115.068213_bib20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1124\/dmd.113.051565","article-title":"Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4","volume":"41","author":"Kato","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1124\/dmd.114.062620","article-title":"A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement","volume":"43","author":"Kazmi","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1124\/dmd.115.065011","article-title":"Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor","volume":"43","author":"Kazmi","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib23","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1124\/dmd.109.028225","article-title":"Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10","volume":"37","author":"Kerdpin","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","article-title":"UDP-glucuronosyltransferases and clinical drug-drug interactions","volume":"106","author":"Kiang","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.115.068213_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/dmd.108.023853","article-title":"Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes","volume":"37","author":"Kilford","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/BF00431808","article-title":"Mianserin protein binding in serum and plasma from healthy subjects and patients with depression and rheumatoid arthritis","volume":"87","author":"Kristensen","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1124\/dmd.115.068213_bib27","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1124\/mol.107.037952","article-title":"Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4","volume":"72","author":"Kubota","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.115.068213_bib28","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1124\/dmd.31.11.1361","article-title":"N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases","volume":"31","author":"Kuehl","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s10517-009-0520-4","article-title":"Experimental and clinical pharmacokinetics of amitryptiline: comparative analysis","volume":"147","author":"Kukes","year":"2009","journal-title":"Bull Exp Biol Med"},{"key":"10.1124\/dmd.115.068213_bib30","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.bcp.2006.12.021","article-title":"Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation","volume":"73","author":"Lewis","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.115.068213_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.115.068213_bib32","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1124\/dmd.111.041418","article-title":"Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9","volume":"39","author":"Manevski","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib33","doi-asserted-by":"crossref","first-page":"e54767","DOI":"10.1371\/journal.pone.0054767","article-title":"Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent","volume":"8","author":"Manevski","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.115.068213_bib34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0163-7258(91)90065-T","article-title":"Drug glucuronidation in humans","volume":"51","author":"Miners","year":"1991","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.115.068213_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.44.101802.121546","article-title":"Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches","volume":"44","author":"Miners","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.115.068213_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03602530903210716","article-title":"The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential","volume":"42","author":"Miners","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.115.068213_bib37","series-title":"Enzyme and Transporter Based Drug-Drug Interactions","first-page":"217","article-title":"The in vitro characterization of inhibitory drug-drug interactions involving UDP-glucuronosyltransferase","author":"Miners","year":"2010"},{"key":"10.1124\/dmd.115.068213_bib38","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1124\/dmd.110.037036","article-title":"Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation","volume":"39","author":"Miners","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/qsar.19870060303","article-title":"Conformational analysis of flexible antidepressant drugs","volume":"6","author":"Munro","year":"1987","journal-title":"Quant Struct-Act Relat"},{"key":"10.1124\/dmd.115.068213_bib40","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/dmd.30.12.1484","article-title":"Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes","volume":"30","author":"Nakajima","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2133\/dmpk.20.227","article-title":"Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation","volume":"20","author":"Nakajima","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.115.068213_bib42","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1124\/dmd.115.065870","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by canagliflozin and dapagliflozin: implications for drug-drug interactions","volume":"43","author":"Pattanawongsa","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1124\/jpet.110.167916","article-title":"In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans","volume":"334","author":"Raungrut","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.115.068213_bib44","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.106.118216","article-title":"Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation","volume":"321","author":"Rowland","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.115.068213_bib46","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.021105","article-title":"The \u201calbumin effect\u201d and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib47","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1124\/dmd.115.068213_bib48","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/dmd.106.009738","article-title":"Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode","volume":"34","author":"Takeda","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib49","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/dmd.105.007369","article-title":"Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) \u201cprobes\u201d for human udp-glucuronosyltransferases","volume":"34","author":"Uchaipichat","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.068213_bib52","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0773.1980.tb01575.x","article-title":"Single dose pharmacokinetics of doxepin in healthy volunteers","volume":"47","author":"Virtanen","year":"1980","journal-title":"Acta Pharmacol Toxicol"},{"key":"10.1124\/dmd.115.068213_bib53","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/dmd.111.043117","article-title":"Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors","volume":"40","author":"Walsky","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.068213_bib54","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1124\/dmd.109.030981","article-title":"Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine","volume":"38","author":"Zhou","year":"2010","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624101675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624101675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.115.068213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:23:04Z","timestamp":1739906584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624101675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0090955624101675"],"URL":"https:\/\/doi.org\/10.1124\/dmd.115.068213","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.115.068213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}